KRW 1446.0
(-0.69%)
Year | Net Debt | Net Debt Growth |
---|---|---|
2023 | 15.02 Billion KRW | 532.08% |
2022 | 2.37 Billion KRW | 120.95% |
2021 | -11.34 Billion KRW | -199.82% |
2020 | -3.78 Billion KRW | -819.47% |
2019 | 526.1 Million KRW | 107.88% |
2018 | -6.67 Billion KRW | -68.06% |
2017 | -3.97 Billion KRW | 31.57% |
2016 | -5.8 Billion KRW | -116.88% |
2015 | -2.67 Billion KRW | 0.0% |
Year | Net Debt | Net Debt Growth |
---|---|---|
2024 Q1 | 15.9 Billion KRW | 5.85% |
2024 Q2 | 9.97 Billion KRW | -37.27% |
2023 Q2 | 11.7 Billion KRW | -56.08% |
2023 Q1 | 26.65 Billion KRW | 1021.29% |
2023 FY | 15.02 Billion KRW | 532.08% |
2023 Q4 | 15.02 Billion KRW | 19.54% |
2023 Q3 | 12.56 Billion KRW | 7.38% |
2022 FY | 2.37 Billion KRW | 120.95% |
2022 Q4 | 2.37 Billion KRW | -86.95% |
2022 Q3 | 18.21 Billion KRW | 0.04% |
2022 Q2 | 18.2 Billion KRW | 72.02% |
2022 Q1 | 10.58 Billion KRW | 193.26% |
2021 Q2 | -26.77 Billion KRW | -1162.77% |
2021 Q3 | -23.99 Billion KRW | 10.4% |
2021 FY | -11.34 Billion KRW | -199.82% |
2021 Q4 | -11.34 Billion KRW | 52.7% |
2021 Q1 | -2.12 Billion KRW | -221.99% |
2020 Q3 | -1.44 Billion KRW | 0.0% |
2020 FY | -3.78 Billion KRW | -819.47% |
2020 Q1 | 561.93 Million KRW | 88.89% |
2020 Q4 | 1.73 Billion KRW | 220.39% |
2019 Q4 | 297.48 Million KRW | 0.0% |
2019 FY | 526.1 Million KRW | 107.88% |
2018 FY | -6.67 Billion KRW | -68.06% |
2017 FY | -3.97 Billion KRW | 31.57% |
2016 FY | -5.8 Billion KRW | -116.88% |
2015 FY | -2.67 Billion KRW | 0.0% |
Name | Net Debt | Net Debt Difference |
---|---|---|
Osang Healthcare Co.,Ltd | -108.91 Billion KRW | 113.795% |
InBody Co.,Ltd | -16.2 Billion KRW | 192.716% |
Curexo Inc. | -15.03 Billion KRW | 199.951% |
Seegene, Inc. | -48.57 Billion KRW | 130.931% |
i-SENS, Inc. | 98.45 Billion KRW | 84.739% |
Ray Co., Ltd. | 67.09 Billion KRW | 77.606% |
Sugentech Inc. | -6.95 Billion KRW | 316.144% |
L&C Bio Co., Ltd | 67.18 Billion KRW | 77.636% |